Corporate calendar for None (QURE): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-15 | ||
| 2026-09-15 | $0.21 | $63M |
| 2026-09-15 | ||
| 2026-09-15 | ||
| 2026-09-15 | ||
| 2026-09-15 | $26M |
Price
| Price | $42.49 |
| Market Cap | $2.9B |
Related companies: ABCL · CLDX · EWTX · GLPG · GPCR · MESO · NUVB
More sections of QURE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks